Blood-Based Biomarkers for Lung Cancer Early Detection and Evaluation of CT-Based Lesions
Final rept. 25 Sep 2010-24 Sep 2013
BRITISH COLUMBIA CANCER AGENCY VANCOUVER
Pagination or Media Count:
This project has two major aims regarding blood based biomarkers 1 develop and test biomarkers capable of detecting lung cancer up to 24 months prior to clinical diagnosis and 2 identify biomarkers that can discriminate benign from malignant lung nodules 5 to 30 mm in size identified by thoracic CT scans. The tasks at the BCCA are 1 integrate genomic profiles mutation, miRNA, methylation and gene expression and published data to identify over-expressed genes that may be potential protein targets and 2 select the best over-expressed miRNA for assessment in pre-validation studies to test for clinical applications. The BCCA team has substantially contributed to successful accomplishment of the two overall aims of the consortium project headed by Dr. Sam Hanash in addition to validation of Pro-surfactant protein B using a unique, well-characterized in terms of age, sex, detailed smoking history, family history, lung function, pathologically validated lung cancer screening dataset from 2,485 high risk current and former smokers with 138 lung cancers in the Pan-Canadian Early Detection of Lung Cancer Study that has 3.3 to 5.5 years of follow-up. In addition, we have discovered a unique set of miRNAs for future biomarker studies.
- Medicine and Medical Research